文献速递心外重症与机械循环支持先天性心脏病外科

EUROMACS第四版儿童机械循环支持报告

The European Registry for Patients with Mechanical Circulatory Support (EUROMACS): fourth Paediatric EUROMACS (Paedi-EUROMACS) report.
PubMed 文献 · Eur J Cardiothorac Surg · 2024-01-01

该报告基于EUROMACS数据库中590例19岁以下VAD植入患者,比较先天性心脏病与非先天性病因两组特征与结局。先天性组更年轻且更多使用搏动流装置,死亡率更高,但多变量分析中先心病与死亡率无显著关联;泵血栓是最常见不良事件。

要点

  • 儿童VAD使用增加,国际注册协作对积累经验至关重要。
  • 先心病组较非先心病组更年轻且更多使用搏动流装置。
  • 泵血栓与体表面积、先心病及搏动流支持在多变量分析中显著相关。

核心结论

  • 第四版Paedi-EUROMACS报告强调儿童VAD使用增加,先天性与非先天性病因患者群体具有不同特征和临床结局。

研究设计与样本

  • 纳入EUROMACS数据库中所有19岁以下接受VAD支持的儿科患者,分为先心病组和非先天性病因组,采用Cox比例风险模型探索死亡、脑血管意外和泵血栓相关因素。

主要发现

  • 共纳入590例初次植入,先心病组显著更年轻(2.5 vs 8.0岁,P < 0.001)且更常用搏动流装置(73.5% vs 59.9%,P < 0.001)。
  • 先心病组死亡率显著高于非先天性组(30.8% vs 20.4%,P = 0.009),但多变量分析中先心病与死亡率无显著关联(HR 1.285;CI 0.8111-2.036,P = 0.740)。
  • 泵血栓是最常见不良事件(132例患者共377次事件;每患者年0.925次事件),多变量分析中与体表面积(HR 0.524,CI 0.333-0.823,P = 0.005)、先心病(HR 1.641,CI 1.054-2.555,P = 0.028)和搏动流支持(HR 2.345,CI 1.406-3.910,P = 0.001)显著相关。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The use of ventricular assist devices (VADs) in children is increasing. However, absolute numbers in individual centres and countries remain small. Collaborative efforts such as the Paedi-European Registry for Patients with Mechanical Circulatory Support (EUROMACS) are therefore essential for combining international experience with paediatric VADs. Our goal was to present the results from the fourth Paedi-EUROMACS report. METHODS: All paediatric (<19 years) patients from the EUROMACS database supported by a VAD were included. Patients were stratified into a congenital heart disease (CHD) group and a group with a non-congenital aetiology. End points included mortality, a transplant and recovery. Cox proportional hazard models were used to explore associated factors for mortality, cerebrovascular accident and pump thrombosis. RESULTS: A total of 590 primary implants were included. The congenital group was significantly younger (2.5 vs 8.0 years, respectively, P < 0.001) and was more commonly supported by a pulsatile flow device (73.5% vs 59.9%, P < 0.001). Mortality was significantly higher in the congenital group (30.8% vs 20.4%, P = 0.009) than in the non-congenital group. However, in multivariable analyses, CHD was not significantly associated with mortality [hazard ratio (HR) 1.285; confidence interval (CI) 0.8111-2.036, P = 0.740]. Pump thrombosis was the most frequently reported adverse event (377 events in 132 patients; 0.925 events per patient-year) and was significantly associated with body surface area (HR 0.524, CI 0.333-0.823, P = 0.005), CHD (HR 1.641, CI 1.054-2.555, P = 0.028) and pulsatile flow support (HR 2.345, CI 1.406-3.910, P = 0.001) in multivariable analyses. CONCLUSIONS: This fourth Paedi-EUROMACS report highlights the increasing use of paediatric VADs. The patient populations with congenital and non-congenital aetiologies exhibit distinct characteristics and clinical outcomes.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Rohde S, van Puyvelde J, Veen KM, et al. The European Registry for Patients with Mechanical Circulatory Support (EUROMACS): fourth Paediatric EUROMACS (Paedi-EUROMACS) report. Eur J Cardiothorac Surg. 2024. PMID: 39029919. doi:10.1093/ejcts/ezae276

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。